In The Know

CiiTA to attend the Medicaid Drug Rebate Conference later this month.

This September 23-25, CiiTA will join experts from around the country to discuss government pricing, rebates, and regulations. As the nationally recognized and neutral thought leader on the 340B Drug Pricing Program, CiiTA has a seat at the table to address the unique impacts 340B presents to Medicaid plan implementation and success. CiiTA’s conference space—Booth…

Read More

CiiTA is moving!

Having outgrown our second location in five years – we are moving to a third! Effective July 6th, CiiTA will be located at 815 SW Second Avenue, Suite 300; Portland, Oregon 97204.  Feel free to come by for a visit!

Read More

CiiTA – A New Brand

You may have noticed some changes to our website and to our message.  We have concluded the first phase of a complete rebranding of CiiTA.  We are pretty excited about this effort and believe that you will be as well. First some background: starting in the mid-2017, we hired Asceta ( to help us understand…

Read More

New Members of the CiiTA Team

As CiiTA continues to grow and evolve, we occasionally get to announce the onboarding of a new teammate. Please join me in welcoming Jason Osieczanek and Pujitha Palem to the CiiTA team. Jason is taking over the role of Office Manager and has already demonstrated his competence and skills in running the back-office functions of…

Read More

Jason Hardaway speaking at the CBI 340B Manufacturer Summit

CiiTA’s Managing Director Jason Hardaway has once again been invited to speak at the 4th Annual 340B Manufacturer Summit being held in Washington DC this August. His topic, “Best Practices for Communicating with States and Covered Entities to Prevent Revenue Leakage,” will be co-presented with Cathy Burton-Meza and Alexis Arroyo. CBI’s 4th Annual 340B Manufacturer…

Read More

HRSA’s Civil Monetary Penalties Rule Postponed (Again!)

The effective date for the 340B Drug Program Ceiling Price and Manufacturer Civil Monetary Penalties has been delayed once again, pushing the date to July 1, 2018. A Final Rule was released today, stating: HHS proposed this action to allow a more deliberate process of considering alternative and supplemental regulatory provisions and to allow for sufficient time…

Read More

The Effect of Medicaid Spending on the 340B Program

Medicaid spending cuts proposed by President Trump and Congressional Republicans Health Care plan would once again change the 340B landscape. In 2010, under the ACA’s Medicaid expansion, more than 11 million uninsured people became newly qualified for benefits. As those patients began receiving care, the number of hospitals that qualified to purchase 340B drugs grew.…

Read More

HRSA’s Civil Monetary Penalties Rule: Finalized, but Postponed

Clients have been asking for our take on the Health Resources and Services Administration (“HRSA”) 340B Drug Pricing Program Ceiling Price and Civil Monetary Penalties Rule (the CMP Rule) from May 22, 2017, until October 1, 2017. This Rule, if and when it becomes effective, imposes monetary penalties on manufacturers of up to $5,000 for…

Read More

CiiTA Team Win

One of the things that makes working at CiiTA enjoyable is the variety of skills and backgrounds of our team members. Marissa Korbel joined our team in late 2016. Marissa has been writing creatively and professionally since her college days. She was recently accepted into the prestigious and competitive Tin House Summer Workshop, which takes…

Read More

BIO Video: Understanding Your Drug Costs

This super short and helpful little video explains why the list price is not really the price anyone pays for their medicine. Great work from the team at BIO.

Read More

Develop Your 340B Strategy

CiiTA has, through extensive experience, developed a set of best practices to help guide you through the creation of your 340B strategy. Download our process document to facilitate the development of your strategy.

Please enter your name.
Please enter a valid email address.
Something went wrong. Please check your entries and try again.